Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis

•Total body weight and lean body muscle were significantly increased in the anamorelin group.•Anamorelin significantly improved the quality of life.•Anamorelin represents a promising treatment for cachexia in lung cancer patients. Cancer anorexia-cachexia syndrome (CACS) is characterized by involunt...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-10, Vol.112, p.25-34
Main Authors: Nishie, Kenichi, Yamamoto, Shuhei, Nagata, Chie, Koizumi, Tomonobu, Hanaoka, Masayuki
Format: Article
Language:English
Subjects:
Age Factors
Anamorelin
Body Weight
Cachexia
Cachexia - drug therapy
Cachexia - etiology
Carcinoma, Non-Small-Cell Lung - complications
Carcinoma, Non-Small-Cell Lung - diagnosis
Clinical Trials as Topic
Humans
Hydrazines - administration & dosage
Hydrazines - adverse effects
Hydrazines - therapeutic use
Lung Neoplasms - complications
Lung Neoplasms - diagnosis
Non-small-cell lung cancer
Odds Ratio
Oligopeptides - administration & dosage
Oligopeptides - adverse effects
Oligopeptides - therapeutic use
Quality of Life
Randomized Controlled Trials as Topic
Sex Factors
Treatment Outcome
Weight loss
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Total body weight and lean body muscle were significantly increased in the anamorelin group.•Anamorelin significantly improved the quality of life.•Anamorelin represents a promising treatment for cachexia in lung cancer patients. Cancer anorexia-cachexia syndrome (CACS) is characterized by involuntary weight loss. CACS is commonly observed in advanced non-small-cell lung cancer (NSCLC), and it leads to a poor quality of life (QOL). No effective standard treatment exists for this condition. However, anamorelin has reportedly caused improvement in patients with several cancers. We conducted a quantitative meta-analysis to explore the efficacy of anamorelin for treating CACS in patients with NSCLC. We systematically searched CENTRAL, MEDLINE, EMBASE, CINAHL, and OvidSP. We pooled the data and calculated and compared total body weight (TBW), lean body mass (LBM), overall survival (OS), hand grip strength (HGS), QOL, and adverse events (AEs) between patients treated with anamorelin (anamorelin group) and those not (placebo group). Six randomized controlled trials included 1641 patients with NSCLC. Both TBW and LBM were significantly increased in the anamorelin group compared to the placebo group (mean differences [MD] 1.78, 95%CI: 1.28–2.28, p
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2017.07.023